Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients
- 10 January 2013
- journal article
- Published by Elsevier BV in Gene
- Vol. 512 (2), 226-231
- https://doi.org/10.1016/j.gene.2012.10.048
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Chronic Kidney Disease After Nonrenal Solid Organ TransplantationTransplantation, 2012
- A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant RecipientsClinical Chemistry, 2011
- The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patientsCancer Chemotherapy and Pharmacology, 2011
- Tacrolimus Concentrations in Relation to CYP3A and ABCB1 Polymorphisms Among Solid Organ Transplant Recipients in KoreaTransplantation, 2009
- Microproteinuria for detecting calcineurin inhibitor-related nephrotoxicity after liver transplantationWorld Journal of Gastroenterology, 2009
- CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental StudyAmerican Journal of Transplantation, 2006
- Multidrug Resistance Gene-1 (MDR-1) Haplotypes Have a Minor Influence on Tacrolimus Dose RequirementsTransplantation, 2006
- Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitorsPharmacogenetics, 2003
- Urinary protein and enzyme excretion as markers of tubular damageCurrent Opinion in Nephrology and Hypertension, 2003
- FK506 NephrotoxicityRenal Failure, 1999